文献速递癫痫

辅助性cenobamate治疗未控制局灶性癫痫的随机对照剂量反应试验

Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial.
PubMed 文献 · Lancet Neurol · 2019-11-14

该多中心、双盲、随机、安慰剂对照、剂量反应研究在16国107中心纳入437例未控制局灶性癫痫成人患者,评估辅助性cenobamate 100、200、400 mg每日一次相比安慰剂的疗效与安全性。结果显示cenobamate呈剂量相关地降低28天局灶性发作频率并提高应答率,但最高剂量组治疗中出现的不良事件及因不良事件停药比例最高。

要点

  • cenobamate 100、200、400 mg均较安慰剂显著降低局灶性发作频率并提高≥50%应答率。
  • 200 mg和400 mg剂量组疗效优于100 mg组,呈现剂量相关趋势。
  • 400 mg组治疗中出现不良事件及因不良事件停药比例最高,需关注耐受性。

核心结论

  • 辅助性cenobamate以剂量相关方式减少局灶性起源发作频率,在未控制局灶性癫痫患者中为有效治疗选择。

研究设计与样本

  • 多中心、双盲、随机、安慰剂对照、剂量反应研究,在16国107个癫痫和神经中心进行。
  • 437例18-70岁局灶性癫痫成人患者按1:1:1:1随机分配至安慰剂或cenobamate 100 mg、200 mg、400 mg每日一次口服组。
  • 研究包括8周基线评估、6周滴定期和12周维持期。
  • 主要疗效终点为改良意向治疗人群的28天局灶性发作频率百分比变化和维持期应答率(≥50%减少)。

主要发现

  • 治疗中出现不良事件发生率:安慰剂组70%(76/108),100 mg组65%(70/108),200 mg组76%(84/110),400 mg组90%(100/111)。
  • 因治疗中出现不良事件停药比例:安慰剂组5%(5/108),100 mg组10%(11/108),200 mg组14%(15/110),400 mg组20%(22/111)。
  • 200 mg cenobamate组发生1例伴嗜酸性粒细胞增多和全身症状的药物反应严重病例,未报告死亡。

临床怎么用

  • 对于尽管使用1-3种抗癫痫药物仍有局灶性发作的成人患者,可考虑辅助性cenobamate治疗。
  • cenobamate疗效呈剂量相关,但400 mg组不良事件及停药比例最高,临床需权衡疗效与耐受性。

局限性

  • 研究仅纳入18-70岁局灶性癫痫成人患者,结论不适用于其他癫痫类型或年龄人群。
  • 维持期人群样本量随剂量组升高而减少(400 mg组95例),可能影响耐受性结果的精确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: More than a third of patients with epilepsy are treatment resistant, and thus new, more effective therapies to achieve seizure freedom are needed. Cenobamate (YKP3089), an investigational antiepileptic drug, has shown broad-spectrum anticonvulsant activity in preclinical studies and seizure models. We aimed to evaluate the safety, efficacy, and tolerability of adjunctive cenobamate in patients with uncontrolled focal (partial)-onset epilepsy. METHODS: We did a multicentre, double-blind, randomised, placebo-controlled, dose-response study at 107 epilepsy and neurology centres in 16 countries. Adult patients (aged 18-70 years) with focal seizures despite treatment with 1-3 antiepileptic drugs were randomly assigned (1:1:1:1) via an interactive web response system, by block sizes of 4 within each country, to adjuvant once daily oral cenobamate at dose groups of 100 mg, 200 mg, or 400 mg, or placebo following an 8-week baseline assessment. Patients, investigators, and study personnel were masked to treatment assignment. The study included a 6-week titration phase and 12-week maintenance phase. The primary efficacy outcomes were percentage change in 28-day focal seizure frequency (focal aware motor, focal impaired awareness, or focal to bilateral tonic-clonic seizures) from baseline analysed in the modified intention-to-treat population (≥1 dose and any post-baseline seizure data) and responder rates (≥50% reduction) analysed in the maintenance phase population (≥1 dose in the maintenance phase and any maintenance phase seizure data). The primary efficacy outcomes were analysed using a hierarchal step-down procedure comparing 200 mg versus placebo, 400 mg versus placebo, then 100 mg versus placebo. Safety and tolerability were compared descriptively across treatment groups for all randomised patients. This study is registered with ClinicalTrials.gov, number NCT01866111. FINDINGS: Between July 31, 2013, and June 22, 2015, 437 patients were randomly assigned to either placebo (n=108) or cenobamate 100 mg (n=108), 200 mg (n=110), or 400 mg (n=111). Of these patients, 434 (106 [98%] in placebo group, 108 [100%] in 100 mg group, 109 [99%] in 200 mg group, and 111 [100%] in 400 mg group) were included in the modified intention-to-treat population, and 397 (102 [94%] in placebo group, 102 [94%] in 100 mg group, 98 [89%] in 200 mg group, and 95 [86%] in 400 mg group) were included in the modified intention-to-treat maintenance phase population. Median percentage changes in seizure frequency were -24·0% (IQR -45·0 to -7·0%) for the placebo group compared with -35·5% (-62·5 to -15·0%; p=0·0071) for the 100 mg dose group, -55·0% (-73·0 to -23·0%; p<0·0001) for the 200 mg dose group, and -55·0% (-85·0 to -28·0%; p<0·0001) for the 400 mg dose group. Responder rates during the maintenance phase were 25% (26 of 102 patients) for the placebo group compared with 40% (41 of 102; odds ratio 1·97, 95% CI 1·08-3·56; p=0·0365) for the 100 mg dose group, 56% (55 of 98; 3·74, 2·06-6·80; p<0·0001) for the 200 mg dose group, and 64% (61 of 95; 5·24, 2·84-9·67; p<0·0001) for the 400 mg dose group. Treatment-emergent adverse events occurred in 76 (70%) of 108 patients in the placebo group, 70 (65%) of 108 in the 100 mg group, 84 (76%) of 110 in the 200 mg group, and 100 (90%) of 111 in the 400 mg group. Treatment-emergent adverse events led to discontinuation in five (5%) patients in the placebo group, 11 (10%) in the 100 mg dose group, 15 (14%) in the 200 mg dose group, and 22 (20%) in the 400 mg dose group. One serious case of drug reaction with eosinophilia and systemic symptoms occurred in the 200 mg cenobamate group. No deaths were reported. INTERPRETATION: Adjunctive cenobamate reduced focal (partial)-onset seizure frequency, in a dose-related fashion. Treatment-emergent adverse events were most frequent in the highest dose group. Cenobamate appears to be an effective treatment option in patients with uncontrolled focal seizures. FUNDING: SK Life Science.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2019. PMID: 31734103. doi:10.1016/S1474-4422(19)30399-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。